MCM
SGMO

Maryland Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Maryland Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,187
Closed -$151K – 257
2021
Q4 		$151K Buy
20,187
+1,242
+7% +$10.8K 0.01% 253
2021
Q3 		$171K Buy
18,945
+1,103
+6% +$10.9K 0.01% 243
2021
Q2 		$214K Sell
17,842
-1,920
-10% -$21.7K 0.01% 247
2021
Q1 		$248K Buy
+19,762
New +$266K 0.02% 219

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Maryland Capital Management's SGMO Position: Q1 2022 in Review

Maryland Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2022, closing a stake of 20,187 shares — an estimated $151K sold.

Maryland Capital Management first reported a position in SGMO in Q1 2021 and held it in 4 quarters. The position peaked at $248K in Q1 2021. 195 funds tracked by Wall St. Rank hold SGMO as of Q1 2022.

  • Maryland Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2022 after selling out during the quarter.
  • Maryland Capital Management sold 20,187 SANGAMO THERAPEUTICS INC shares in Q1 2022, an estimated $151K.
  • Maryland Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2021 and held it in 4 quarters.
  • Maryland Capital Management's SANGAMO THERAPEUTICS INC position peaked at $248K in Q1 2021.
  • 195 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2022.

Based on Maryland Capital Management's 13F filing for Q1 2022, filed 12 May 2022.